|
Clinical Efficacy and Safety Evaluation of Advanced NSCLC Treated by Gemcitabine Combined Platin or Cisplatin
XUE Yan-hong, WANG Lai-cheng, HU Li-li,*, YANG Bo
2018, 15(3):
136-139.
Objective To compare the two gemcitabine related chemotherapy regimens(gemcitabine (GEM) in combination with cisplatin (DDP) or nedaplatin(NDP)) on non-small cell lung cancer(NSCLC), analyze the differences of curative effect and adverse drug reactions (ADR), and provide reference to clinical individualized regimen. Methods The 58 cases diagnosed with NSCLC patients in Xuzhou Medical University Affiliated Hospital between January 2015 and April 2017 were divided into 2 groups, 30 cases of NDP combined with GEM (GN), 28 cases of DDP combined with GEM (GP), treatment cycles within 21 days. Recorded ADR of each cycle of chemotherapy regimens; evaluated curative effect using CT when the third cycle chemotherapy had been finished, then analyzed the adverse reactions and curative effect between the two regimens. Results GN regimen effective rate is 43.33%, GP is 42.86%, there is no significant difference (P>0.05). Gastrointestinal symptoms incidences of NP are lower than GP regimens (P<0.05), and there are no statistical significant differences in decreasing of NEUT, WBC, HGB and PLT, liver toxicity, kidney toxicity(P>0.05). Conclusion Curative effect of GN is similar to GP, and the gastrointestinal reaction of GN is slighter, good tolerance, without hydration treatment. From the effectiveness and safety considerations, GN scheme is comparable with GP for treatment options.
References |
Related Articles |
Metrics
|